Faes Farma in figures
Faes Farma, a national pharmaceutical company founded in 1933, has a solid presence in Spain and Portugal, with a broad and growing international development, with presence in numerous countries and exporting raw materials and finished pharmaceutical products to a growing number of nations.
For the development of research, production and marketing of pharmaceutical products, Faes Farma has a workforce of 1,292 people (by June 30, 2019), in its headquarters in Lejona (Vizcaya), offices in Madrid, Vitoria Laboratories in Portugal, Diafarm Laboratories in Barcelona, and its subsidiaries in Italy, Mexico, Colombia, Peru, Chile, Ecuador and Nigeria; including its animal nutrition companies (FARM Faes) such as Ingaso Farm and Tecnovit.
One of the the biggest results of the pharmaceutical research activity of Faes Farma is the launch of our antihistamine molecule bilastine, marketed in Spain since 2011 and licensed in more than 120 countries throughout the world.
Faes Farma Group ended 2018 with a turnover of 324.3 million euros, which represents an improvement of 18.1% compared to 2017. This positive evolution reaffirms the trend of previous years and driven this year for the full-year integration of the three new subsidiaries acquired in 2017 (ITF, Diafarm and Tecnovit) and the notable improvement in the perimeter turnover prior to these purchases.
Also noteworthy is the positive evolution of the “Other Operating Income” caption, doubling the amount achieved in 2017, thanks to the magnificent performance of the licenses granted, both for bilastine and for other molecules.
Faes Farma Group ended 2018 with a Consolidated Net Profit of 51.59 million euros, with an increase of 24.7% compared to 2017, obtaining in 2018 the highest profit in its history.